1. IVERIC Bio Announces the Addition of Mark S. Blumenkranz, M.D., M.M.S., to its Board of Directors

    IVERIC Bio Announces the Addition of Mark S. Blumenkranz, M.D., M.M.S., to its Board of Directors

    IVERIC bio, Inc. (NASDAQ: ISEE) announced today the election of Mark S. Blumenkranz, M.D., M.M.S., HJ Smead Professor Emeritus of Ophthalmology at Stanford University, to its Board of Directors, effective as of July 15, 2020. Dr. Blumenkranz is an internationally known vitreo-retinal specialist, with notable contributions in the area of novel pharmaceuticals for macular diseases, ocular gene therapy, new laser systems, and ophthalmic tele-health and technology development...

    Read Full Article

    Login to comment.

  1. Categories

    1. BoardProspects Features:

      BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, In the News, Partner Publications, Question of The Week, Sponsored Content
  2. Quotes

    1. As a highly-recognized retinal specialist and co-founder of multiple biotechnology and medical technology companies, Mark's ophthalmic expertise and extensive business experience will be of tremendous value as we continue to advance our pipeline of therapeutics for age-related retinal diseases and gene therapy product candidates for inherited retinal diseases.
    2. Mark's experience in leading and building biotechnology companies, further strengthens our board and represents a valuable addition to the Company.
  3. Topics Mentioned